Newly-diagnosed Pediatric T-cell ALL Protocol

This is a prospective, multicenter study conducted within the Chinese Children's Cancer Group (CCCG). The study aims to evaluate whether the addition of three novel agents, dasatinib, venetoclax and homoharringtonine, can improve the minimal residual disease (MRD)-negative remission rate, enhance event-free survival (EFS), and reduce the cumulative incidence of relapse (CIR) in pediatric patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL).

Trial Details

NCT ID

NCT06855810

Phase

PHASE2 / PHASE3

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

Venetoclax
Dasatinib
homoharringtonine

Locations (sample)

Hefei, Anhui, China|31.86389,117.28083
Hefei, Anhui, China|31.86389,117.28083
Chongqing, Chongqing Municipality, China|29.56026,106.55771
Fuzhou, Fujian, China|26.06139,119.30611
Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Age older than 1 month to younger than 18 years.
Diagnosis of acute lymphoblastic leukemia by bone marrow morphology.
Diagnosis of T-ALL by immunophenotyping.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →